{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050158","form_type":"8-K","ticker":"OMDA","cik":"0001611115","company_name":"Omada Health, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.917746+00:00","generated_at":"2026-05-16T23:42:48.300952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Omada Health Q3 revenue $68M (+49% YoY); first positive adjusted EBITDA $2M","bullets":["Revenue $68M, up 49% YoY; members 831K, up 53% YoY.","Net loss $3M vs $9M loss prior year; first quarter of positive adjusted EBITDA of $2M.","Gross margin 66% (non-GAAP 68%), up from 63% (65%) in Q3 2024.","Announced new GLP-1 prescribing offering combining behavior change with anti-obesity medications.","Cash and equivalents $199M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050158","json":"https://secwatch.observer/filing/0001628280-25-050158.json","markdown":"https://secwatch.observer/filing/0001628280-25-050158.md","text":"https://secwatch.observer/filing/0001628280-25-050158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1611115/000162828025050158/0001628280-25-050158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1611115/000162828025050158/omda-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:42:48.300952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}